Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

<p>Abstract</p> <p>Background</p> <p>We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis.</p> <p...

Full description

Bibliographic Details
Main Authors: Palacios Santiago, Kung Annie WC, Fernandes César E, Brown Jacques P, Adachi Jonathan D, Chesnut Charles H, Christiansen Claus, Levine Amy B, Chines Arkadi A, Constantine Ginger D
Format: Article
Language:English
Published: BMC 2010-06-01
Series:BMC Musculoskeletal Disorders
Online Access:http://www.biomedcentral.com/1471-2474/11/130

Internet

http://www.biomedcentral.com/1471-2474/11/130

Similar Items